Immuno-viral therapy as a new approach for the treatment of brain tumors

Drug News and Perspectives

Volumn 16, Issue 4, 2003, Pages 223-229

  Toda, Masahiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

BRAIN TUMOR; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOMODULATION; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS REPLICATION;

BRAIN NEOPLASMS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MUTATION; NEOPLASM METASTASIS; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 0042433483     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.4.829334     Document Type: Review

References (61)

1. Pelner, L., Fowler, G.A. and Hauts, H.C. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand 1958, 338(Suppl): 1-47.
2. Moore, A.E. The oncolytic viruses. Prog Exp Tumor Res 1960, 1: 411-39.
3. Asada, T. Treatment of human cancer with mumps virus. Cancer 1974, 34: 1907-28.
4. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. and Martuza, R.L. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995, 1: 938-43.
5. Markert, J.M., Medlock, M.D., Rabkin, S.D. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000, 7: 867-74.
6. Bischoff, J.R., Kirn, D.H., Williams, A. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274: 373-6.
7. Khuri, F.R., Nemunaitis, J., Ganly, I. et al. A controlled trial of intrutumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6: 879-85.
8. Nemunaitis, J., Ganly, I., Khuri, F. et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000, 60: 6359-66.
9. McGeoch, D.J., Dalrymple, M.A., Davison, A.J. et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 1988, 69: 1531-74.
10. DeLuca, N.A. and Schaffer, P.A. Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4. J Virol 1988, 62: 732-43.
11. Everett, R.D. The regulation of transcription of viral and cellular genes by herpesvirus immediate-early gene products. Anticancer Res 1987, 7: 589-604.
12. Sandri-Goldin, R.M. and Mendoza, G.E. A herpesvirus regulatory protein appears to act post-transcriptionally by affecting mRNA processing. Genes Dev 1992, 6: 848-63.
13. Chou, J. and Roizman, B. The gamma I(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992, 89: 3266-70.
14. Goldstein, D.J. and Weller, S.K. Herpes simplex virus type I-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988, 62: 196-205.
15. Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.G. et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 1989, 86: 4736-40.
16. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. and Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252: 854-6.
17. Hunter, W., Rabkin, S. and Martuza, R. Brain tumor therapy using genetically engineered replication-competent virus. In: Viral Vectors. M.G. Kaplitt and A.D. Loewy (Eds.). Academic Press, San Diego 1995, pp. 259-74.
18. Hunter, W.D., Martuza, R.L., Feigenbaum, F. et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999, 73: 6319-26.
19. Patchell, R.A. Brain metastases. Neuro Clin 1991, 9: 817-24.
20. Zimm, S., Wampler, G.L., Stablein, D., Hazra, T. and Young, H.F. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 1981, 48:384-94.
21. Penar, P.L. and Wilson, J.T. Cost and survival analysis of metastatic cerebral tumors treated by resection and radiation. Neurosurgery 1994, 34: 888-93.
22. Auchter, R.M., Lamond, J.P., Alexander, E. et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996, 35: 27-35.
23. Bindal, A.K., Bindal, R.K., Hess, K.R. et al. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 1996, 84: 748-54.
24. Colak, A., Goodman, J.C., Chen, S.-H., Woo, S.L.C., Grossman, R.G. and Shine, H.D. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther 1995, 6: 1317-22.
25. Randazzo, B.P., Kesari, S., Gesser, R.M. et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 1995, 211: 94-101.
26. Toda, M., Rabkin, S.D. and Martuza, R.L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998, 9: 2177-85.
27. Walker, J.R., McGeagh, K.G., Sundaresan, P., Jorgensen, T.J., Rabkin, S.D. and Martuza, R.L. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999, 10: 2237-43.
28. Kooby, D.A., Carew, J.F., Halterman, M.W. et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Faseb J 1999, 13: 1325-34.
29. Coukos, G., Makrigiannakis, A., Montas, S. et al. Multi-attenuated helpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000, 7: 275-83.
30. Chahlavi, A., Todo, T., Martuza, R.L. and Rabkin, S.D. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999, 1: 162-9.
31. Bindal, R.K., Sawaya, R., Leavens, M.E. and Lee, J.J. Surgical treatment of multiple brain metastases. J Neurosurg 1993, 79: 210-6.
32. Boone, C.W., Paranjpe, M., Orme, T. and Gillette, R. Virus-augmented tumor transplantation antigens: Evidence for a helper antigen mechanism. Int J Cancer 1974, 13: 543-51.
33. Freedman, R.S., Bowen, J.M., Herson, J.H., Wharton, J.T., Edwards, C.L. and Rutledge, F.N. Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. Obstet Gynecol 1983, 62: 707-14.
34. Cassel, W.A., Murray, D.R. and Phillips, H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983, 52: 856-60.
35. Kobayashi, H., Gotohda, E., Hosokawa, M. and Kodama, T. Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor. J Natl Cancer Inst 1975, 54: 997-9.
36. Toda, M., Rabkin, S.D., Kojima, H. and Martuza, R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999, 10: 385-93.
37. Huang, A.Y.C., Gulden, P.H., Woods, A.S. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996, 93: 9730-5.
38. Toda, M., Martuza, R.L. and Rabkin, S.D. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 2001, 8: 332-9.
39. Toda, M., Iizuka, Y., Kawase, T., Uyemura, K. and Kawakami, Y. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 2002, 9: 356-64.
40. Kovacsovics-Bankowski, M. and Rock, K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995, 267: 243-6.
41. Reis, E., Sousa, C. and Germain, R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995, 182: 841-51.
42. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10: 281-7.
43. Andreansky, S.S., He, B., Gillespie, G.Y. et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996, 93: 11313-8.
44. Kucharczuk, J.C., Randazzo, B., Chang, M.Y. et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997, 57: 466-71.
45. Todo, T., Martuza, R.L., Rabkin, S.D. and Johnson, P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001, 98: 6396-401.
46. Harland, J., Papanastassiou, V. and Brown, S.M. HSV1716 persistence in primary human glioma cells in vitro. Gene Ther 2002, 9: 1194-8.
47. Becher, B., Prat, A. and Antel, J.P. Brain-immune connection: Immuno-regulatory properties of CNS-resident cells. Glia 2000, 29: 293-304.
48. Wekerle, H. T-cell autoimmunity in the central nervous system. Intervirology 1993, 35: 95-100.
49. Fabry, Z., Raine, C.S. and Hart, M.N. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol Today 1994, 15: 218-24.
50. Zeine, R. and Owens, T. Direct demonstration of the infiltration of murine central nervous system by Pgp-1/CD44 high CD45RB (low) CD4+ T cells that induce experimental allergic encephalomyelitis. J Neuroimmunol 1992, 40: 57-69.
51. Toda, M., Martuza, R.L., Kojima, H. and Rabkin, S.D. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998, 160: 4457-64.
52. Toda, M., Martuza, R.L. and Rabkin, S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000, 2: 324-9.
53. Toda, M., Iizuka, Y., Yazaki, T., Kawase, K., Uyemura, K. and Kawakami, Y. In situ cancer vaccination using a mutant HSV-1 for the treatment of metastatic brain tumor. Neuro-Oncology 1999, 1: Abst S105.
54. Endo, T., Toda, M., Watanabe, M. et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002, 9: 142-8.
55. Schackert, H.K., Itaya, T., Schackert, G., Fearon, E., Vogelstein, B. and Frost, P. Systemic immunity against a murine colon tumor (CT-26) produced by immunization with syngeneic cells expressing a transfected viral gene product. Int J Cancer 1989, 43: 823-7.
56. Irani, D.N., Lin, K.I. and Griffin, D.E. Regulation of brain-derived T cells during acute central nervous system inflammation. J Immunol 1997, 158: 2318-26.
57. Irani, D.N. Brain-derived gangliosides induce cell cycle arrest in a murine T cell line. J Neuroimmunol 1998, 87: 11-6.
58. Walker, A.E., Robins, M. and Weinfeld, F.D. Epidemiology of brain tumors: The national survey of intracranial neoplasms. Neurology 1985, 35: 219-26.
59. Delattre, J.Y., Krol, G., Thaler, H.T. and Posner, J.B. Distribution of brain metastasis. Arch Neurol 1988, 45: 741-4.
60. Whitley, R.J. Herpes simplex viruses. In: Fields Virology. Third edition, vol. 2. B.N. Fields, D.M. Knipe and P.M. Howley (Eds.). Lippincott-Raven, Philadelphia 1996, pp. 2297-342.
61. Davison, M.J., Preston, V.G. and McGeoch, D.J. Determination of the sequence alteration in the DNA of the herpes simplex virus type 1 temperature-sensitive mutant tsK. J Gen Virol 1984, 65: 859-63.